Varicella vaccine - GlaxoSmithKline
Latest Information Update: 03 Jul 2025
At a glance
- Originator GSK
- Class Attenuated vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Varicella zoster virus infections
Most Recent Events
- 15 May 2025 Phase-III clinical trials in Varicella zoster virus infections (In infants, Prevention) in Dominican Republic (SC) (NCT06806137)
- 17 Apr 2025 GlaxoSmithKline initiates phase-III clinical trials in Varicella zoster virus infections (Prevention, In infants) in USA (SC) (NCT06855160)
- 10 Jan 2025 Phase-III clinical trials in Varicella zoster virus infections (Prevention, In infants) in USA (SC) (NCT06740630)